Envudeucitinib vs Fadeucravacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
Envudeucitinib
Developed by Alumis and partners
NCT06586112 · Phase 3 · completed
Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2027 · NCT05739435 (registry estimate)
Reported efficacy
To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)
Result source: NCT06586112
Fadeucravacitinib
Developed by Beijing InnoCare Pharma Tech Co.
NCT06109818 · Phase 2 · completed
The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.
Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12. (Baseline up to Week 12): PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved (met)
Result source: NCT06109818
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Envudeucitinib | Fadeucravacitinib |
|---|---|---|
| PASI 75 | 56.4% vs 0%+56.4 vs placeboNCT056000364 other results
| —Trial running · NCT06842199 |
| PASI 90 | —Not posted · NCT06588738 | —Trial running · NCT06842199 |
| PASI 100 | —Not posted · NCT06588738 | —Trial running · NCT06842199 |
| sPGA 0/1 | 53.8% vs 7.9%+45.9 vs placeboNCT056000364 other results
| —Trial running · NCT06842199 |
| DLQI, change | —Not posted · NCT06588738 | —Trial running · NCT06842199 |
PASI 75
- Envudeucitinib
- 56.4% vs 0%+56.4 vs placeboNCT05600036
4 other results
- 64.1% vs 0% NCT05600036
- 33.3% vs 0% NCT05600036
- 56.4% vs 0% NCT05600036
- 19.4% vs 0% NCT05600036
- Fadeucravacitinib
- —Trial running · NCT06842199
PASI 90
- Envudeucitinib
- —Not posted · NCT06588738
- Fadeucravacitinib
- —Trial running · NCT06842199
PASI 100
- Envudeucitinib
- —Not posted · NCT06588738
- Fadeucravacitinib
- —Trial running · NCT06842199
sPGA 0/1
- Envudeucitinib
- 53.8% vs 7.9%+45.9 vs placeboNCT05600036
4 other results
- 59% vs 7.9% NCT05600036
- 38.9% vs 7.9% NCT05600036
- 48.7% vs 7.9% NCT05600036
- 16.7% vs 7.9% NCT05600036
- Fadeucravacitinib
- —Trial running · NCT06842199
DLQI, change
- Envudeucitinib
- —Not posted · NCT06588738
- Fadeucravacitinib
- —Trial running · NCT06842199
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Envudeucitinib: 4 of 4 rows · Fadeucravacitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Envudeucitinib |
|---|---|
| Dropout rate | 10.3%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results15.4%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 7.5%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 16.7%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results2.6%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 5.6%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results2.6%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 7.7%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 0%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 2.8%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40mg BIDa headache 7.7% (placebo 5.3%) nasopharyngitis 7.7% (placebo 7.9%) upper respiratory tract infection 7.7% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results40mg QD headache 10.3% (placebo 5.3%) acne 5.1% (placebo 0%) upper respiratory tract infection 5.1% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 20mg BID headache 7.7% (placebo 5.3%) cough 5.1% (placebo 0%) diarrhea 5.1% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 20mg QD headache 5.6% (placebo 5.3%) upper respiratory tract infection 5.6% (placebo 0%) acne 0% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 10mg QD diabetes mellitus 5.6% (placebo 0%) nasopharyngitis 5.6% (placebo 7.9%) upper respiratory tract infection 5.6% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Envudeucitinib
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envudeucitinib's landscape · Fadeucravacitinib's landscape